Organization
National Cancer Centre
25 clinical trials
Clinical trial
A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II Trial to Compare Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab) Versus Selective Internal Radiation Therapy (SIRT-Y90) Followed by Placebo in Patients With Locally Advanced Hepatocellular Carcinoma (HCC)Status: Recruiting, Estimated PCD: 2025-04-26
Clinical trial
An Open-label, Single-institution, Dose-determining (Part 1) and Dose-confirmatory (Part II) Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients Harboring Different TCF20 rs932376 Variant AllelesStatus: Active (not recruiting), Estimated PCD: 2025-11-01
Clinical trial
A Phase II Multi-Centre Study Evaluating the Efficacy of Dacomitinib for Patients With Epidermal Growth Factor Receptor (EGFR)-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expression or Other Novel Emerging BiomarkersStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
An Open Label Phase II Study of the Efficacy and Tolerability of PRL3-ZUMAB and Predictive Biomarkers in Advanced Solid TumoursStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Peritoneal MetastasesStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Radical Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of High Risk Recurrent Retroperitoneal SarcomaStatus: Active (not recruiting), Estimated PCD: 2022-02-28
Clinical trial
A Phase II Open-Label, Single Centre, Non-Randomised Trial Of Y90-Radioembolization In Combination With Nivolumab In Asian Patients With Advanced Hepatocellular CarcinomaStatus: Active (not recruiting), Estimated PCD: 2019-08-31
Clinical trial
A Phase II Study of Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients.Status: Recruiting, Estimated PCD: 2026-02-28
Clinical trial
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC (SOS-1 Study)Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Phase II Investigator Sponsored Multi-Centre Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Patients With Relapsed or Refractory Marginal Zone LymphomaStatus: Terminated, Estimated PCD: 2020-07-17
Clinical trial
Phase Ib Study Evaluating Safety and Tolerability of Combination Trametinib and Ruxolitinib in Patients With Advanced RAS Mutant Colorectal Cancer and Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2023-06-30
Clinical trial
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III TrialStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Longitudinal Immune-phenotyping of Surgically Resected HCC Following Neoadjuvant and Adjuvant Treatment With MK-3475Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells From a Mesenchymal-Like to an Epithelial-Like PhenotypeStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
The Utility of LiverMultiScan Analysis of MRI Scans in Patients With Hepatocellular Carcinoma for Improved Prognostication and as an Aid to the Selection of TherapyStatus: Completed, Estimated PCD: 2021-03-16
Clinical trial
A Single-arm, Open-label, Phase 2 Study of Dacomitinib With or Without Dose Titration for the First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Subjects With an Epidermal Growth Factor Receptor (EGFR) Activation MutationStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Clinical trial
Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell CancerStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase II Trial Of Ipilimumab In Combination With Nivolumab In Patients With Advanced Nasopharyngeal CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
An Open Label, Single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) Vaccine and Anti-PD1 (Nivolumab) as Adjuvant Treatment in Resected Hepatocellular Carcinoma (HCC) (Group A) and Liver Metastases From Colorectal Cancer (CRLM) (Group B)Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole in the Advanced Setting - a Phase II StudyStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
RIBBON-LA-01: Single-arm, Open-label, Phase 2 Trial of Tislelizumab and Metronomic Capecitabine as Maintenance Therapy in High-risk Locoregionally-advanced Nasopharyngeal CarcinomaStatus: Not yet recruiting, Estimated PCD: 2028-10-01
Clinical trial
Phase II Study of Nimotuzumab (TheraCim-hR3) Concurrent With Cisplatin/Radiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)Status: Completed, Estimated PCD: 2019-09-03
Clinical trial
A Phase Ib Trial of Gefitinib (EGFR Tyrosine Kinase Inhibitor, Iressa™) in Combination With BKM120, an Oral Pan-class I PI3K Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFRStatus: Completed, Estimated PCD: 2016-02-22
Clinical trial
Window of Opportunity Study With Neoadjuvant Pembrolizumab in Colorectal CancerStatus: Recruiting, Estimated PCD: 2024-08-01